Page 80 - 《中国药房》2021年24期

综上所述，目前在我国DXM+RTX方案治疗成人慢 update[J]. Hematology Am Soc Hematol Educ Program，
性 ITP 的经济性主要体现为长期获益，若是考虑到对于 2018，2018（1）：568-575.
慢性疾病的长期管理，DXM+RTX方案相比单用方案具 [11] World Health Organization. The global health observa-
有经济性。另外，RTX在我国还没有被批准用于ITP的 tory[EB/OL].（2020-12-04）[2021-11-12]. https：//www.
治疗，在将来相关适应证获批上市并进入医保目录后， who.int/data/gho/data/indicators/indicator-details/GHO/
费用很有可能会进一步降低，届时联用疗法的经济性会 life-expectancy-at-age-60-（years）.
更加凸显。 [12] WANG T，XU M，JI L，et al. Splenectomy for adult chro-
参考文献 nic idiopathic thrombocytopenic purpura：experience from

[ 1 ] PROVAN D，STASI R，NEWLAND A C，et al. Inter- a single center in China[J]. Eur J Haematol，2005，75（5）：
national consensus report on the investigation and ma- 424-429.
nagement of primary immune thrombocytopenia[J]. Blood， [13] ZHOU H，QIN P，LIU Q，et al. A prospective，multicenter
2010，115（2）：168-186. study of low dose decitabine in adult patients with refrac-
[ 2 ] KAYAL L，JAYACHANDRAN S，SINGH K. Idiopathic tory immune thrombocytopenia[J]. Am J Hematol，2019，
thrombocytopenic purpura[J]. Contemp Clin Dent，2014，5 94（12）：1374-1381.
（3）：410-414. [14] World Health Organization. The global health observa-
[ 3 ] WEYCKER D，HANAU A，HATFIELD M，et al. Primary tory[EB/OL].（2020-12-06）[2021-11-12]. https：//www.
immune thrombocytopenia in US clinical practice：inci- who.int/data/gho/data/indicators/indicator-details/GHO/
dence and healthcare burden in first 12 months following gho-ghe-life-tables-by-country.
diagnosis[J]. J Med Econ，2020，23（2）：184-192. [15] PORTIELJE J E，WESTENDORP R G，KLUIN-NELEMANS
[ 4 ] DANESE M D，LINDQUIST K，GLEESON M，et al. H C，et al. Morbidity and mortality in adults with idiopa-
Cost and mortality associated with hospitalizations in pa- thic thrombocytopenic purpura[J]. J Am Soc Hematol，
tients with immune thrombocytopenic purpura[J]. Am J 2001，97（9）：2549-2554.
Hematol，2009，84（10）：631-635.
[16] 刘国恩.中国药物经济学评价指南：2020[M].北京：中国
[ 5 ] ZHOU Z，YANG L，CHEN Z，et al. Health-related quality
市场出版社，2020：27-28.
of life measured by the short form 36 in immune thrombo-
[17] SANZ M A，ALEDORT L，MATHIAS S D，et al. Analysis
cytopenic purpura：a cross-sectional survey in China[J].
of EQ-5D scores from two phase 3 clinical trials of romi-
Eur J Haematol，2007，78（6）：518-523.
plostim in the treatment of immune thrombocytopenia
[ 6 ] KHELLAF M，LE MOINE J G，POITRINAL P，et al.
（ITP）[J]. Value Health，2011，14（1）：90-96.
Costs of managing severe immune thrombocytopenia in
[18] LEE D，THORNTON P，HIRST A，et al. Cost effective-
adults：a retrospective analysis[J]. Ann Hematol，2011，90
ness of romiplostim for the treatment of chronic immune
（4）：441-446.
thrombocytopenia in Ireland[J]. Appl Health Econ Health
[ 7 ] AN R，WANG P P. Length of stay，hospitalization cost，
Policy，2013，11（5）：457-469.
and in-hospital mortality in US adult inpatients with
[19] MCNAMARA R L，LIMA J A，WHELTON P K，et al.
immune thrombocytopenic purpura，2006-2012[J]. Vasc
Health Risk Manag，2017，13：15-21. Echocardiographic identification of cardiovascular sources
[ 8 ] 中华医学会血液学分会止血与血栓学组.成人原发免疫 of emboli to guide clinical management of stroke：a
性血小板减少症诊断与治疗中国指南：2020年版[J]. 中 cost-effectiveness analysis[J]. Ann Intern Med，1997，127
华血液学杂志，2020，41（8）：617-623. （9）：775-787.
[ 9 ] GUDBRANDSDOTTIR S，BIRGENS H S，FREDERIKSEN [20] XIE F，BLACKHOUSE G，ASSASI N，et al. Results of a
H，et al. Rituximab and dexamethasone vs dexamethasone model analysis to estimate cost utility and value of infor-
monotherapy in newly diagnosed patients with primary mation for intravenous immunoglobulin in Canadian
immune thrombocytopenia[J]. Blood，2013，121（11）： adults with chronic immune thrombocytopenic purpura[J].
1976-1981. Clin Ther，2009，31（5）：1082-1091.
[10] NEUNERT C E，COOPER N. Evidence-based manage- （收稿日期：2020-11-25 修回日期：2021-11-15）
ment of immune thrombocytopenia：ASH guideline （编辑：孙 冰）

·3018 · China Pharmacy 2021 Vol. 32 No. 24 中国药房 2021年第32卷第24期